Efficacy and Safety of DHEA for Myotonic Dystrophy
Phase 3 Study of Oral Dehydroepiandrosterone (DHEA) in Adults With Myotonic Dystrophy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Angers, France
- CHU
-
Bordeaux, France
- CHU
-
Garches, France, 92380
- Raymond Poincaré Hospital
-
Grenoble, France
- CHU
-
Lyon, France
- CHU
-
Marseilles, France
- CHU Pouget
-
Nice, France
- CHU
-
Paris, France
- Institut de Myologie
-
Strasbourg, France
- CHU
-
Toulouse, France
- CHU
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Myotonic dystrophy (genetically proven)
- MDRS score of 3 or 4
Exclusion Criteria:
- Age <18 years or >70 years
- Pregnancy or breastfeeding
- Poor compliance to treatment and follow up
- Inclusion in any other clinical trial
- Severe cardiac disease: acute myocardial infarction in the preceding 6 months, unstable heart failure, uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >100 mmHg after 10 minutes of rest in the lying position), severe arteritis, any past history of thrombose or embolic event, any past history of symptomatic arrhythmia)
- Chronic renal failure
- Chronic liver disease
- Long term mechanical ventilation
- Any ongoing cancer
- Any underlying endocrine disorders
- Impaired swallowing
- Previous treatment with DHEA
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Variation in a Muscle Strength Score between randomization and study week 12
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
evaluation of myotonia
Time Frame: 3 months
|
3 months
|
|
Appeal score
Time Frame: 3 months
|
3 months
|
|
Epworth score
Time Frame: 3 months
|
3 months
|
|
Forced vital capacity
Time Frame: 3 months
|
3 months
|
|
arterial blood gas
Time Frame: 3 months
|
3 months
|
|
changes in EKG and echocardiography
Time Frame: 3 months
|
3 months
|
|
tolerance
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: martine devillers, MD, AFM
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Genetic Diseases, Inborn
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Muscular Disorders, Atrophic
- Heredodegenerative Disorders, Nervous System
- Muscular Dystrophies
- Myotonic Disorders
- Myotonic Dystrophy
- Physiological Effects of Drugs
- Immunologic Factors
- Adjuvants, Immunologic
- Dehydroepiandrosterone
Other Study ID Numbers
Other Study ID Numbers
- P001108
- PS001108
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.